Compare ARK Genomic Revolution ETF (ARKG) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs UnitedHealth Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while UnitedHealth Group Inc trades at $425.8 (market cap $385.62B). The key difference: UnitedHealth Group Inc pays a 2.19% dividend while ARK Genomic Revolution ETF pays none, and UnitedHealth Group Inc is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | UNH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $431.68 |
52-Week Low | $23.09 | $237.77 |
Market Cap | — | $385.62B |
Enterprise Value | — | $432.30B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
UnitedHealth Group (UNH) trades at $424.62, down 1.64% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $7.23 versus $6.58 expected. Revenue grew to $447.57 billion in 2025, though net income margin compressed to 2.68%. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
UNH presents a favorable risk-reward profile with 82.7% analyst buy ratings and a consensus price target of $423.18, near the current price. Key opportunities include demographic tailwinds from an aging population and tech-driven efficiency gains. Risks involve regulatory scrutiny, as seen in Massachusetts' Medicaid lawsuit, and margin pressure from rising costs. The stock's valuation at a P/E of 31.97 requires sustained earnings growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
